Published in the Red Journal, this study reported the late GI and GU toxicities of 54 patients with high-risk or unfavorable intermediate risk prostate cancer treated with IMPT to a total dose of 67.5 GyRBE to the prostate and 45 GyRBE to pelvic lymph nodes in 25 daily fractions. Median follow-up was 43.9 months. The actuarial rate of late grade ≥2 GI toxicity at both 2 and 3 years was 7.4%. The actuarial rate of late grade 3 GI toxicity at both 2 and 3 years was 1.9%. The actuarial rate of late grade ≥2 GU toxicity was 20.5% at 2 years, and 29.2 % at 3 years. None had grade 3 GU toxicity.